Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance to Acquire Lark Technologies for $19.9M

NEW YORK, Dec. 19 (GenomeWeb News) - Genaissance Pharmaceuticals announced today that it will acquire Lark Technologies of Houston, Texas in an all stock transaction worth about $19.9 million.


The deal has been approved by both companies' boards of directors and is expected to close in the first half of 2004, subject to shareholder approval.


Lark is a research genomic service company that offers services for use in pharmaceutical, diagnostic, and agricultural product research and development. Genaissance expects to take in $25 million in pro forma revenues for 2004, plus a reduced operating loss and expanded service and technology portfolio, as a result of the transaction, according to the company.


"The acquisition of Lark is an exciting next step in the execution of our strategy to build a profitable base services business while developing proprietary products based on our HAP Technology.


Carl Balezentis, Lark's president and CEO, will join Genaissance as senior vice president and president, Lark Technologies.



The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.